Clinical Trials Browser

Interventional × Infectious Mononucleosis × Bendamustine Hydrochloride × Clear all

NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Phase 2 Withdrawn

Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms